RU2007139912A - Способ прогнозирования течения рака на основе количественного анализа клеточного рецептора витамина фолата - Google Patents

Способ прогнозирования течения рака на основе количественного анализа клеточного рецептора витамина фолата Download PDF

Info

Publication number
RU2007139912A
RU2007139912A RU2007139912/15A RU2007139912A RU2007139912A RU 2007139912 A RU2007139912 A RU 2007139912A RU 2007139912/15 A RU2007139912/15 A RU 2007139912/15A RU 2007139912 A RU2007139912 A RU 2007139912A RU 2007139912 A RU2007139912 A RU 2007139912A
Authority
RU
Russia
Prior art keywords
cancer cells
cells
cancer
antibody
vitamin
Prior art date
Application number
RU2007139912/15A
Other languages
English (en)
Russian (ru)
Inventor
Филип Стюарт ЛОУ (US)
Филип Стюарт ЛОУ
Линн К. ХАРТМАНН (US)
Линн К. ХАРТМАНН
Кристофер Пол ЛИМОН (US)
Кристофер Пол Лимон
Фил Роналд ЭЛЛИС (US)
Фил Роналд ЭЛЛИС
Original Assignee
Пердью Рисерч Фаундейшн (Us)
Пердью Рисерч Фаундейшн
Эндосайт, Инк. (Us)
Эндосайт, Инк.
Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Ричерч (Us)
Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Ричерч
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пердью Рисерч Фаундейшн (Us), Пердью Рисерч Фаундейшн, Эндосайт, Инк. (Us), Эндосайт, Инк., Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Ричерч (Us), Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Ричерч filed Critical Пердью Рисерч Фаундейшн (Us)
Publication of RU2007139912A publication Critical patent/RU2007139912A/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
RU2007139912/15A 2005-03-30 2006-03-30 Способ прогнозирования течения рака на основе количественного анализа клеточного рецептора витамина фолата RU2007139912A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66643005P 2005-03-30 2005-03-30
US60/666,430 2005-03-30

Publications (1)

Publication Number Publication Date
RU2007139912A true RU2007139912A (ru) 2009-05-10

Family

ID=36754569

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2007139912/15A RU2007139912A (ru) 2005-03-30 2006-03-30 Способ прогнозирования течения рака на основе количественного анализа клеточного рецептора витамина фолата

Country Status (10)

Country Link
US (1) US20090081710A1 (https=)
EP (2) EP2199796A1 (https=)
JP (1) JP2008537778A (https=)
CN (1) CN101203759A (https=)
AT (1) ATE460668T1 (https=)
AU (1) AU2006230219A1 (https=)
CA (1) CA2602585A1 (https=)
DE (1) DE602006012816D1 (https=)
RU (1) RU2007139912A (https=)
WO (1) WO2006105141A1 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE427948T1 (de) 2001-04-24 2009-04-15 Purdue Research Foundation Folat-mimetika und deren folatrezeptorbindende konjugate
CA2484640C (en) 2002-05-15 2012-01-17 Endocyte, Inc. Vitamin-mitomycin conjugates
WO2004069159A2 (en) 2003-01-27 2004-08-19 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates
EP3101034A1 (en) 2004-02-12 2016-12-07 Morphotek, Inc. Monoclonal antibodies that specifically bind to folate receptor alpha
CN101098854B (zh) 2004-07-23 2012-12-05 恩多塞特公司 二价连接体及其轭合物
CN101175757B (zh) 2005-03-16 2012-11-14 恩多塞特公司 蝶酸及其缀合物的合成和纯化
CA2607444C (en) 2005-04-22 2015-03-10 Morphotek, Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
BRPI0615354A2 (pt) 2005-08-19 2011-05-17 Endocyte, Inc. conjugado de liberação de fármaco de ligação de receptor, composição farmacêutica que o compreende, bem como seu uso
US20100104626A1 (en) 2007-02-16 2010-04-29 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
AU2008224988A1 (en) 2007-03-14 2008-09-18 Endocyte, Inc. Binding ligand linked drug delivery conjugates of tubulysins
CN101784565B (zh) 2007-06-25 2014-12-10 恩多塞特公司 含有亲水性间隔区接头的共轭物
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
CN101909441B (zh) 2007-10-25 2015-05-13 恩多塞特公司 微管蛋白抑制剂及其制备方法
BR112012002064A2 (pt) * 2009-07-31 2017-05-09 Endocyte Inc método para determinar se ec145 é indicado para o tratamento de um paciente com um tumor ovariano ou um tumor de pulmão; método para prever uma resposta de um tumor ovariano ou um tumor de pulmão de um paciente a terapia com ec145; método de tratamento de câncer ovariano resistente à platina em um paciente necessitando dele; uso de ec145 em combinação com doxorrubicina lipossômica peguilada; uso de ec145 para a fabricação de um medicamento; método para obter um benefício clínico comparado a tratamento com uma quantidade terapêutica de doxorrubicina lipossômica peguilada no tratamento de câncer ovariano resistente à platina em um paciente necessitando dele; método para selecionar um paciente para tratamento; composição farmacêutica; unidade de dosagem, método para determinar se um paciente com um tumor tem receptores de folato funcionalmente ativos presentes no tumor do paciente; método de tratamento de um tumor epitelial expressando receptor de folato em um paciente necessitando dele; e; método para obter um benefício clínico no tratamento de um tumor epitelial expressando receptor de folato em um paciente necessitando dele
TWI622402B (zh) 2010-02-24 2018-05-01 免疫遺傳股份有限公司 葉酸受體１抗體類和免疫共軛物類及彼等之用途
MX343607B (es) * 2010-11-05 2016-11-11 Morphotek Inc Receptor alfa de folato como marcador de diagnóstico y pronóstico para cánceres que expresan receptor alfa de folato.
KR20130140032A (ko) * 2010-11-12 2013-12-23 엔도사이트, 인코포레이티드 암을 치료하는 방법들
BR112013025415B1 (pt) * 2011-04-01 2021-03-16 Immunogen, Inc uso de um imunoconjugado antirreceptor de folato 1 (folr1)
SI2731972T1 (en) 2011-07-15 2018-04-30 Eisai R&D Management Co., Ltd. Anti-folate receptor alpha antibodies and uses thereof
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
US9200073B2 (en) 2012-08-31 2015-12-01 Immunogen, Inc. Diagnostic assays and kits for detection of folate receptor 1
CN102861020A (zh) * 2012-09-25 2013-01-09 上海交通大学医学院附属仁济医院 叶酸在制备预防大肠腺瘤初发药物中的应用
BR112015008365A2 (pt) 2012-10-16 2017-07-04 Endocyte Inc composto da fórmula b-l(d)x, ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composição de forma de dosagem unitária ou dose unitária, composição para tratar um câncer em um paciente, e método para tratar um câncer em um paciente
US20140154702A1 (en) * 2012-11-30 2014-06-05 Endocyte, Inc. Methods For Treating Cancer Using Combination Therapies
CN113150145B (zh) 2013-08-30 2025-02-14 伊缪诺金公司 用于检测叶酸受体1的抗体和测定
PL3055332T3 (pl) * 2013-10-08 2020-02-28 Immunogen, Inc. Schematy dawkowania immunokoniugatu anty-FOLR1
WO2015077303A1 (en) 2013-11-19 2015-05-28 Purdue Research Foundation Patient selection method for inflammation
JP6246030B2 (ja) * 2014-03-12 2017-12-13 東芝メディカルシステムズ株式会社 病理染色装置及び病理染色方法
CN116440279B (zh) 2015-09-17 2026-02-24 伊缪诺金公司 包含抗folr1免疫缀合物的治疗组合
US11313868B2 (en) * 2016-06-14 2022-04-26 Board Of Regents, The University Of Texas System Methods of detecting anti-folic acid antibodies and uses thereof
CN106483282B (zh) * 2016-09-29 2018-08-31 北京世纪沃德生物科技有限公司 一种抗原稳定剂及其制备方法与应用
EP3544999A1 (en) 2016-11-23 2019-10-02 Eisai R&D Management Co., Ltd. Anti-folate receptor alpha antibodies and uses thereof
CN116615455A (zh) * 2020-09-12 2023-08-18 免疫医疗有限公司 用于抗b7h4抗体-药物缀合物疗法的评分方法
CN117741149A (zh) * 2024-02-19 2024-03-22 卡秋(江苏)生物科技有限公司 一种用于卵巢癌细胞叶酸受体α的检测试剂盒及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5989838A (en) 1992-03-11 1999-11-23 Institute Of Virology, Slovak Academy Of Sciences Immunological methods of detecting MN proteins and MN polypeptides
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
US5846739A (en) * 1995-12-05 1998-12-08 Wisconsin Alumni Research Foundation Immunohistochemical detection assay for carcinoma proliferative status
US6358682B1 (en) 1998-01-26 2002-03-19 Ventana Medical Systems, Inc. Method and kit for the prognostication of breast cancer
CN1441676B (zh) * 2000-03-31 2012-08-22 普渡研究基金会 用配体-免疫原缀合物治疗的方法
EP2168598A1 (en) * 2001-09-28 2010-03-31 Purdue Research Foundation Method of Treatment Using Ligand-Immunogen Conjugates
WO2003089593A2 (en) * 2002-04-19 2003-10-30 Endocyte, Inc. Adjuvant enhanced immunotherapy
CA2484640C (en) 2002-05-15 2012-01-17 Endocyte, Inc. Vitamin-mitomycin conjugates
WO2004069159A2 (en) 2003-01-27 2004-08-19 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates

Also Published As

Publication number Publication date
EP2199796A1 (en) 2010-06-23
EP1864133A1 (en) 2007-12-12
AU2006230219A1 (en) 2006-10-05
EP1864133B1 (en) 2010-03-10
WO2006105141A1 (en) 2006-10-05
ATE460668T1 (de) 2010-03-15
US20090081710A1 (en) 2009-03-26
CN101203759A (zh) 2008-06-18
CA2602585A1 (en) 2006-10-05
JP2008537778A (ja) 2008-09-25
DE602006012816D1 (de) 2010-04-22

Similar Documents

Publication Publication Date Title
RU2007139912A (ru) Способ прогнозирования течения рака на основе количественного анализа клеточного рецептора витамина фолата
Huang et al. Correlation of ALDH 1, CD 44, OCT 4 and SOX 2 in tongue squamous cell carcinoma and their association with disease progression and prognosis
Sahin et al. Ki‐67 immunostaining in node‐negative stage I/II breast carcinoma. Significant correlation with prognosis
Savci-Heijink et al. The role of desmoglein-3 in the diagnosis of squamous cell carcinoma of the lung
Tchou et al. Fibroblast activation protein expression by stromal cells and tumor-associated macrophages in human breast cancer
ES2535723T3 (es) Métodos de determinación de la respuesta del paciente mediante la medición de Her-3
Hoshino et al. Prognostic significance of the proliferative potential of intracranial gliomas measured by bromodeoxyuridine labeling
Werner et al. Current status of molecular biomarkers in endometrial cancer
Kim et al. Prognostic implications of immunohistochemically detected YKL-40 expression in breast cancer
Lv et al. Nestin expression is associated with poor clinicopathological features and prognosis in glioma patients: an association study and meta-analysis
JP2008537778A5 (https=)
CN108179134B (zh) 基于EpCAM/PSMA双抗体功能化微流控芯片及其制备方法和应用
CN102298053B (zh) 原发性肝细胞肝癌术后复发风险评估的组合抗体试剂盒
RU2016104892A (ru) Композиции и способы для идентификации риска развития ракового заболевания у субъекта
WO2005100999A3 (en) Functional immunohistochemical cell cycle analysis as a prognostic indicator for cancer
Matikas et al. Prognostic role of serum thymidine kinase 1 kinetics during neoadjuvant chemotherapy for early breast cancer
Yang et al. The ratio of serum Angiopoietin-1 to Angiopoietin-2 in patients with cervical cancer is a valuable diagnostic and prognostic biomarker
CN109975549B (zh) 肿瘤来源IgG在胰腺癌诊断或预后中的用途
CN111912983A (zh) 一种检测多发性骨髓瘤微小残留病变的抗体组合物及试剂盒和应用
Rutter et al. Influence of a 21-gene recurrence score assay on chemotherapy delivery in breast cancer
Cabrera et al. Hepatocellular carcinoma immunopathogenesis: clinical evidence for global T cell defects and an immunomodulatory role for soluble CD25 (sCD25)
CN1928563A (zh) 乳腺癌的免疫组化诊断试剂盒和测试片
IL190401A0 (en) Antibodies against april as biomarkers for early prognosis of lymphoma patients
RU2008111144A (ru) Способы моделирования и ингибирования миграции раковых клеток
Cho et al. Diagnostic and prognostic impact of osteopontin expression in endometrial cancer